Management of Microalbuminuria
Definition and Diagnosis
- Microalbuminuria is defined as urinary albumin excretion of 30-299 mg/24 hours or albumin-to-creatinine ratio of 30-299 μg/mg creatinine in a spot urine sample, according to the American Diabetes Association 3, 2, 4
- Diagnosis requires at least 2 out of 3 positive tests over a 3-6 month period, with the preferred screening method being spot urine albumin-to-creatinine ratio, as recommended by the American Diabetes Association 3, 2, 5
Clinical Significance
- Microalbuminuria represents the earliest stage of diabetic nephropathy and predicts progression to macroalbuminuria and end-stage renal disease, as stated by the American Diabetes Association 3
Management Approach
1. Blood Pressure Control
- The American Diabetes Association recommends target blood pressure of <130/80 mmHg, with first-line agents being ACE inhibitors for type 1 diabetes with any degree of albuminuria, and either ACE inhibitors or ARBs for type 2 diabetes with microalbuminuria 1, 7
- Additional agents, such as non-dihydropyridine calcium channel blockers, β-blockers, and diuretics, may be used if needed to reach target blood pressure, as suggested by the American Diabetes Association 6, 1
2. Glycemic Control
- The American Diabetes Association recommends optimizing glycemic control with target HbA1c <7%, and intensive diabetes management can delay onset and progression of microalbuminuria, according to the American Journal of Kidney Diseases and the American Diabetes Association 8, 2, 4
3. Protein Restriction
- The American Diabetes Association suggests limiting protein intake to 0.8 g/kg body weight/day, with further restriction to 0.6 g/kg/day potentially beneficial in selected patients, and protein-restricted meal plans should be designed by a registered dietitian 1, 7
4. Lipid Management
- The American Diabetes Association recommends aggressive lipid management, with some evidence suggesting that lowering cholesterol may reduce proteinuria, as stated by the American Diabetes Association 3
Monitoring
- The American Diabetes Association recommends monitoring serum potassium levels when using ACE inhibitors or ARBs, continuing surveillance of albuminuria to assess response to therapy, and monitoring renal function with estimated GFR calculations, as suggested by the American Diabetes Association 1, 7, 2, 4, 5